WallStreetZenWallStreetZen

NASDAQ: ETON
Eton Pharmaceuticals Inc Stock

$3.59+0.00 (+0%)
Updated Jul 17, 2024
ETON Price
$3.59
Fair Value Price
N/A
Market Cap
$92.23M
52 Week Low
$2.42
52 Week High
$5.81
P/E
89.75x
P/B
5.95x
P/S
2.74x
PEG
N/A
Dividend Yield
N/A
Revenue
$35.30M
Earnings
$913.00k
Gross Margin
67.2%
Operating Margin
1.54%
Profit Margin
2.6%
Debt to Equity
0.99
Operating Cash Flow
$6M
Beta
0.84
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ETON Overview

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ETON scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ETON is poor value based on its earnings relative to its share price (89.75x), compared to the US market average (30.24x)
P/E vs Market Valuation
ETON is good value based on its earnings relative to its share price (89.75x), compared to the US Drug Manufacturers - Specialty & Generic industry average (-2.32x)
P/E vs Industry Valuation
ETON is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more ETON due diligence checks available for Premium users.

Be the first to know about important ETON news, forecast changes, insider trades & much more!

ETON News

Valuation

ETON price to earnings (PE)

For valuing profitable companies with steady earnings
Company
89.75x
Industry
-2.32x
Market
30.24x
ETON is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ETON is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

ETON price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
5.95x
Industry
2.28x
ETON is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ETON's financial health

Profit margin

Revenue
$8.0M
Net Income
-$811.0k
Profit Margin
-10.2%
ETON's Earnings (EBIT) of $542.00k... subscribe to Premium to read more.
Interest Coverage Financials
ETON's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$30.8M
Liabilities
$15.3M
Debt to equity
0.99
ETON's short-term assets ($24.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ETON's short-term assets ($24.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ETON's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ETON's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.5M
Investing
-$1.9M
Financing
-$378.0k
ETON's operating cash flow ($5.89M)... subscribe to Premium to read more.
Debt Coverage Financials

ETON vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
ETON$92.23M0.00%89.75x5.95x
SCYX$81.98M-2.69%1.02x1.11x
TKNO$78.38M+42.22%-1.85x0.94x
EGRX$77.66M-0.50%6.50x0.31x
INCR$111.20M+0.83%-6.72x0.92x

Eton Pharmaceuticals Stock FAQ

What is Eton Pharmaceuticals's quote symbol?

(NASDAQ: ETON) Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol ETON. Eton Pharmaceuticals stock quotes can also be displayed as NASDAQ: ETON.

If you're new to stock investing, here's how to buy Eton Pharmaceuticals stock.

What is the 52 week high and low for Eton Pharmaceuticals (NASDAQ: ETON)?

(NASDAQ: ETON) Eton Pharmaceuticals's 52-week high was $5.81, and its 52-week low was $2.42. It is currently -38.21% from its 52-week high and 48.35% from its 52-week low.

How much is Eton Pharmaceuticals stock worth today?

(NASDAQ: ETON) Eton Pharmaceuticals currently has 25,690,562 outstanding shares. With Eton Pharmaceuticals stock trading at $3.59 per share, the total value of Eton Pharmaceuticals stock (market capitalization) is $92.23M.

Eton Pharmaceuticals stock was originally listed at a price of $6.25 in Nov 13, 2018. If you had invested in Eton Pharmaceuticals stock at $6.25, your return over the last 5 years would have been -42.56%, for an annualized return of -10.5% (not including any dividends or dividend reinvestments).

How much is Eton Pharmaceuticals's stock price per share?

(NASDAQ: ETON) Eton Pharmaceuticals stock price per share is $3.59 today (as of Jul 17, 2024).

What is Eton Pharmaceuticals's Market Cap?

(NASDAQ: ETON) Eton Pharmaceuticals's market cap is $92.23M, as of Jul 18, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Eton Pharmaceuticals's market cap is calculated by multiplying ETON's current stock price of $3.59 by ETON's total outstanding shares of 25,690,562.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.